


*We make life
easier on
dialysis*

Weakid



www.projectcordial.eu



Contact us via cordial@umcutrecht.nl

Transforming dialysis

Weakid is a new portable device that comes to innovate the world of peritoneal dialysis, benefiting renal patients, clinicians and public health systems compared with current techniques



Weakid...

- ✓ Small, portable home dialysis device that is competitive to in-center hemodialysis (more costly, difficult to combine with work)
- ✓ Continuously recirculates and regenerates the dialysate, remove toxins by adsorption, achieves greater blood purification (1.5-2x) than conventional devices
- ✓ Does not require very high concentrations of glucose, that might damage the peritoneal membrane

The 21st century pandemic

Why Weakid is needed?

**850 M
people**

suffering from renal
disease worldwide

**The 5th greatest
cause of death**

by 2040 will be chronic kidney
disease, and the 2nd before the end
of the century in countries
with longer life expectancy

250K cases

diagnosed every
year

4M people

in the world depending
on dialysis techniques

What are we looking for?

We are open to study any kind of
collaborations from private partners,
capital investment or industry facilitators,
interested in a cooperation aimed to
accelerate the commercialisation of the
Weakid device

WEAKID

Innovative device for
home-based peritoneal
dialysis

Market opportunities



Weakid is an ideal solution for home dialysis



High clearance, easy to use, treatment autonomy and less dialysis fluid volumes




Reduction in health care costs as home dialysis requires less nursing personnel, what is attractive for medical insurance companies



Potential game changer in dialysis therapy: shift from in-center hemodialysis to convenient, efficient and safe treatment at home



Anticipated market share may reach 25% (3 billion euros annually)




Looking for investors

Weakid needs your boost to grow

Preclinical proof of concept already completed

Clinical trials planned to start in 2023, consisting of a first-in-human study & a crossover feasibility study



Usability test carried out in The Netherlands, Italy and Spain

Your alliance: scale-up and commercialization

Why invest in Weakid?

- ✓ Clearly differentiated innovative product with no current competition
- ✓ Competitive performance and operational costs
- ✓ Covers an urgent need in the field of health worldwide
- ✓ No need from funding at the clinical trial phase, already covered by the EU's H2020 programme

Who is developing Weakid



CORDIAL is a three year European project, in which two clinical studies with PD patients will be performed in order to validate the clinical safety and performance of the Weakid device.

Together with patients and clinical personnel, we will explore and evaluate how to make the system available to patients.



CORDIAL is a cooperation of nephrology departments from three European hospitals: UMC Utrecht (NL), UNIMORE (IT) and SERMAS (ES); and two companies: Nanodialysis (NL) and PPI Healthcare Consulting (UK).



UMC Utrecht



UNIMORE
UNIVERSITÀ DEGLI STUDI DI
MODENA E REGGIO EMILIA



SaludMadrid

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz



NANODIALYSIS



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945207

August, 2023